Results 71 to 80 of about 2,329 (147)

DataSheet1_Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.docx

, 2022
Ozanimod, a sphingosine 1-phosphate (S1P) receptor modulator, binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5), and is approved in multiple countries for treating adults with relapsing forms of multiple sclerosis (MS ...
Yingzhuo Grace Yan (12887108), Julie V. Selkirk (12887105), Andrea Bortolato (1276053), Nathan Ching (12887111), Richard Hargreaves (269258)   +4 more
core   +1 more source

Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report

Frontiers in Immunology
BackgroundWe report the first case of findings suggestive of progressive multifocal leukoencephalopathy and immune restitution syndrome (PML-IRIS) in a patient with multiple sclerosis receiving ozanimod preceded by an unexpected increase in the serum ...
Carlos Quintanilla-Bordás, David Gorriz, Laura Cubas-Núñez, Jéssica Castillo-Villalba, Joan Carreres-Polo, Bonaventura Casanova, Francisco Carlos Pérez-Miralles   +6 more
doaj   +1 more source

Specificity of ozanimod and its metabolite RP-101075 on S1P receptors.

, 2018
Specificity of ozanimod and its metabolite RP-101075 on S1P receptors.
Bryan Clemons (5047685), Matthew E. Stokes (5047688), Gregory J. Opiteck (3087825), Fiona L. Scott (5047676), Marcos W. Steinberg (49347), Robert Peach (5047679), Kristen R. Taylor Meadows (5047682)   +6 more
core   +1 more source

INVESTIGATING THE ROLE OF NATURAL KILLER (NK) CELLS IN OZANIMOD-MEDIATED REMISSION IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE) IN C57BL/6 MICE [PDF]

, 2022
Experimental autoimmune encephalomyelitis (EAE) is an important model of multiple sclerosis (MS) in rodents. The disease is characterized by axonal damages mediated by activated autoreactive T lymphocytes, microglia, and macrophages.
Kamyan, Doua Youssef
core  

Cardiovascular safety of ozanimod in patients with ulcerative colitis: True North and open-label extension analyses

BACKGROUND & AIMS: Evaluating cardiovascular safety of sphingosine 1-phosphate (S1P) receptor modulators is warranted due to S1P receptor expression on cardiomyocytes and vascular endothelial cells.
et al.,, Deepak, Parakkal, Armuzzi, Alessandro   +2 more
core   +1 more source

Modern Strategies in the Pharmacotherapy of Inflammatory Bowel Diseases – A Literature Review

Journal of Education, Health and Sport
Introduction and Aim: Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic, immune-mediated disorders of the gastrointestinal tract.
Bartłomiej Czarnecki , Wiktor Werenkowicz, Aleksandra Boral, Dominika Kryś, Joanna Brzoza, Julia Koczur, Michał Górski, Wiktoria Pniok, Wojciech Kurkiewicz   +8 more
doaj   +1 more source

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

, 2019
BACKGROUND Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable ...
Arnold DL, Sheffield JK, Steinman L, Hartung HP, Ding N, Comi G, Bar-Or A, Cohen JA, Raghupathi K, Kubala Havrdová E, Kappos L, Montalban X, Minton N, Cree BAC, Selmaj KW   +14 more
core   +1 more source

Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS

Neurology and Therapy
Introduction Cognitive dysfunction represents a major burden in multiple sclerosis (MS). The impact on cognitive outcomes of ozanimod in real-world settings remains to be fully elucidated.
Aurora Zanghì, Paola Sofia Di Filippo, Carlo Avolio, Emanuele D’Amico   +3 more
doaj   +1 more source

Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

Medicina
Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, necessitates long-term medical therapy to manage symptoms and prevent complications.
Krishneel Dutt, Abhinav Vasudevan
doaj   +1 more source

Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
ObjectiveSphingosine-1-phosphate receptor (S1PR) modulators have recently attracted increasing attention for the treatment of multiple sclerosis (MS).
Xiping Yang, Yan Yan, Suyao Liu, Zhiqing Wang, Xia Feng   +4 more
doaj   +1 more source